These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 33531453

  • 1. Efficacy of Beraprost Sodium Combined with Sildenafil and Its Effects on Vascular Endothelial Function and Inflammation in Patients Experiencing Left Heart Failure Complicated with Pulmonary Arterial Hypertension.
    Sun D, Yang W, Wang Z, Gao B.
    Med Sci Monit; 2021 Feb 03; 27():e928413. PubMed ID: 33531453
    [Abstract] [Full Text] [Related]

  • 2. Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
    Hussain I, Mohammed SF, Forfia PR, Lewis GD, Borlaug BA, Gallup DS, Redfield MM.
    Circ Heart Fail; 2016 Apr 03; 9(4):e002729. PubMed ID: 27072860
    [Abstract] [Full Text] [Related]

  • 3. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
    Belyavskiy E, Ovchinnikov A, Potekhina A, Ageev F, Edelmann F.
    BMC Cardiovasc Disord; 2020 Sep 10; 20(1):408. PubMed ID: 32912157
    [Abstract] [Full Text] [Related]

  • 4. Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure.
    Malhotra R, Dhakal BP, Eisman AS, Pappagianopoulos PP, Dress A, Weiner RB, Baggish AL, Semigran MJ, Lewis GD.
    Circ Heart Fail; 2016 Jun 10; 9(6):. PubMed ID: 27301469
    [Abstract] [Full Text] [Related]

  • 5. A study of the efficacy of sacubitril/valsartan plus dapagliflozin combination treatment in pulmonary arterial hypertension due to left heart disease.
    Ge T, Yang Y, Zhao Y.
    Perfusion; 2023 Nov 10; 38(8):1697-1704. PubMed ID: 36173344
    [Abstract] [Full Text] [Related]

  • 6. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension.
    Liu LC, Hummel YM, van der Meer P, Berger RM, Damman K, van Veldhuisen DJ, Voors AA, Hoendermis ES.
    Eur J Heart Fail; 2017 Jan 10; 19(1):116-125. PubMed ID: 27873388
    [Abstract] [Full Text] [Related]

  • 7. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
    Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, van Veldhuisen DJ, Voors AA.
    Eur Heart J; 2015 Oct 07; 36(38):2565-73. PubMed ID: 26188003
    [Abstract] [Full Text] [Related]

  • 8. Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.
    Borlaug BA, Lewis GD, McNulty SE, Semigran MJ, LeWinter M, Chen H, Lin G, Deswal A, Margulies KB, Redfield MM.
    Circ Heart Fail; 2015 May 07; 8(3):533-41. PubMed ID: 25782985
    [Abstract] [Full Text] [Related]

  • 9. Effect of sildenafil on pulmonary hypertension associated with left heart failure.
    Wu N, Yang G.
    J Biol Regul Homeost Agents; 2018 May 07; 32(3):577-581. PubMed ID: 29921383
    [Abstract] [Full Text] [Related]

  • 10. Left ventricular function in pulmonary hypertension.
    Amano H, Toyoda S, Arikawa T, Inami S, Otani N, Nishi Y, Kitagawa Y, Taguchi I, Abe S, Inoue T.
    Heart Vessels; 2013 Jul 07; 28(4):505-9. PubMed ID: 23124961
    [Abstract] [Full Text] [Related]

  • 11. Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction.
    Andersen MJ, Hwang SJ, Kane GC, Melenovsky V, Olson TP, Fetterly K, Borlaug BA.
    Circ Heart Fail; 2015 May 07; 8(3):542-50. PubMed ID: 25857307
    [Abstract] [Full Text] [Related]

  • 12. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial.
    Cooper TJ, Cleland JGF, Guazzi M, Pellicori P, Ben Gal T, Amir O, Al-Mohammad A, Clark AL, McConnachie A, Steine K, Dickstein K.
    Eur J Heart Fail; 2022 Jul 07; 24(7):1239-1248. PubMed ID: 35596935
    [Abstract] [Full Text] [Related]

  • 13. The immediate effect of sildenafil on right ventricular function in patients with heart failure measured by cardiac magnetic resonance: a randomized control trial.
    Fernandes AM, Andrade AC, Barroso ND, Borges IC, Carvalho-Andrade D, Rodrigues Junior ES, Guimarães LC, Durães AR, Borges SM, Aras Junior R.
    PLoS One; 2015 Jul 07; 10(3):e0119623. PubMed ID: 25793988
    [Abstract] [Full Text] [Related]

  • 14. Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension.
    Corboz MR, Plaunt AJ, Malinin V, Li Z, Gauani H, Chun D, Cipolla D, Perkins WR, Chapman RW.
    Eur J Pharmacol; 2022 Feb 05; 916():174484. PubMed ID: 34508752
    [Abstract] [Full Text] [Related]

  • 15. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF, McKie PM, Dunlay SM, Stevens SR, Felker GM, Borlaug BA, Chen HH, Tracy RP, Braunwald E, Redfield MM.
    J Am Heart Assoc; 2017 Feb 18; 6(2):. PubMed ID: 28214792
    [Abstract] [Full Text] [Related]

  • 16. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
    Guazzi M, Vicenzi M, Arena R, Guazzi MD.
    Circulation; 2011 Jul 12; 124(2):164-74. PubMed ID: 21709061
    [Abstract] [Full Text] [Related]

  • 17. Sildenafil in heart transplant candidates with pulmonary hypertension.
    de Groote P, El Asri C, Fertin M, Goéminne C, Vincentelli A, Robin E, Duva-Pentiah A, Lamblin N.
    Arch Cardiovasc Dis; 2015 Jul 12; 108(6-7):375-84. PubMed ID: 25921840
    [Abstract] [Full Text] [Related]

  • 18. Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF.
    Jiang R, Wang L, Zhu CT, Yuan P, Pudasaini B, Zhao QH, Gong SG, He J, Liu JM, Hu QH.
    Hypertens Res; 2015 Dec 12; 38(12):829-39. PubMed ID: 26202179
    [Abstract] [Full Text] [Related]

  • 19. Development of a Human Model for the Study of Effects of Hypoxia, Exercise, and Sildenafil on Cardiac and Vascular Function in Chronic Heart Failure.
    Damy T, Hobkirk J, Walters M, Ciobanu A, Rigby AS, Kallvikbacka-Bennett A, Guellich A, Dubois-Randé JL, Hittinger L, Clark AL, Cleland JG.
    J Cardiovasc Pharmacol; 2015 Sep 12; 66(3):229-38. PubMed ID: 25874853
    [Abstract] [Full Text] [Related]

  • 20. Perfusion lung scan as a prognostic indicator of response to beraprost sodium in idiopathic pulmonary arterial hypertension.
    Park SY, Moon DH, Park YB, Na JO, Whang HK, Lim BS, Lee SD.
    Pulm Pharmacol Ther; 2006 Sep 12; 19(4):264-71. PubMed ID: 16139536
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.